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Abstract
Midazolam (MDZ), a benzodiazepine derivative, is metabolized to 10 - and
4-hydroxylated metabolites (10 -OH-MDZ and 4-OH-MDZ, respectively) by
cytochrome P450 3A (CYP3A). The purpose of this study was to investigate
the CYP3A-mediated hydroxylation of MDZ in the rat brain mitochondria
(MT). Brain microsomes (MC) and MT fractions were prepared from rats
(n = 8) using differential and density gradient centrifugations, and the purity
of the fractions was evaluated using VDAC1 and calreticulin as markers of
MT and MC, respectively. The formation rates of 10 -OH-MDZ and 4-OHMDZ in the rat brain MC and MT samples were determined using an LC–
MS/MS method after validation. Subsequently, Michaelis–Menten kinetics
of 10 - and 4-hydroxylation of MDZ were estimated. Western blot
(WB) analysis was used to determine the protein expression of CYP3A in
the rat brain MC and MT. The MC fractions had 5.93%  3.01% mitochondrial impurity, and the MT fractions had 19.3%  7.8% microsomal impurity
(mean  SD). The maximum velocity (Vmax) values of the formation of the
hydroxylated metabolites in the brain MT were 2.4–9-fold higher than those
in MC. Further, the Vmax values of 4-OH-MDZ in both MC and MT fractions
were substantially higher than those of 10 -OH-MDZ. The WB analysis
showed that the intensity of the CYP3A immunoreactive band in MT was
more than twofold higher than that in MC. It is concluded that compared with
MC, rat brain MT contains substantial CYP3A, which may affect the pharmacology or toxicology of centrally acting xenobiotic and endogenous substrates of this enzyme.
KEYWORDS
brain, CYP3A, cytochrome P450, microsomes, midazolam hydroxylation, mitochondria

List of Abbreviations/Acronyms: %RSD, %relative standard deviation; %RE,
%relative error; 10 -OH-MDZ, 10 -hydroxymidazolam; 4-OH-MDZ,
4-hydroxymidazolam; CLint, intrinsic clearance; CLmax, maximum clearance;
CPR, NADPH-cytochrome P450 reductase; CYP3A, cytochrome P450 3A; KM,
Michaelis–Menten constant; MC, microsomes; MDZ, midazolam; MM,
Michaelis–Menten; MT, mitochondria; n, Hill coefficient; P450, cytochrome
P450; S, substrate concentration; S50, substrate concentration producing half
of Vmax in the Hill equation; Vmax, maximum velocity; WB, Western blot.
Nouf Alshammari and Devaraj Venkatapura Chandrashekar have contributed
equally to this study.

1 | INTRODUCTION
Cytochrome P450 (P450) enzymes are a superfamily
of biotransformation enzymes responsible for the oxidation of a majority of endogenous and exogenous compounds [1, 2]. Many P450 enzymes are involved in
drug metabolism in the body and have a significant role
in the pharmacokinetics, toxicokinetics, and clinical
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response of drugs. Although the liver contains the highest levels of P450 in the body, these enzymes are also
present in extrahepatic tissues, including the brain
[3–5]. However, in the brain, the levels of P450
enzymes are relatively low and constitute 1% to 10% of
that in the liver [6].
In contrast to the liver, where the majority of P450
enzymes reside in the endoplasmic reticulum
(i.e., microsomes [MC]), P450 studies in the brain suggest that the P450 contents of the mitochondria
(MT) are the same as or even higher than those in the
MC [7–11]. The presence of P450 enzymes in the
brain, although at a much lower abundance than that in
the liver, may have clinical ramifications in terms of the
effects or toxicity of the centrally acting drugs [12–14],
the synthesis of endogenous neurotransmitters, such
as serotonin and dopamine [15, 16], or the metabolism
of arachidonic acid [17]. Because of the relatively high
mitochondrial contents of brain P450, it is necessary to
study the mitochondrial P450 in addition to their microsomal counterparts in the brain tissue.
Among subfamilies of P450, CYP3A subfamily comprises the most abundant P450 enzymes in humans,
which are extensively expressed in the liver and gastrointestinal tract [18]. Additionally, RT-PCR, Western blot
(WB), and enzymatic activity studies have confirmed
that CYP3A isoforms are present in both human and
animal brains [19–25]. Therefore, it is crucial to study
the expression and activity of CYP3A isoforms in the
brain MC and MT. However, there are limited data with
respect to the activity of CYP3A in the brain MC and
MT. This limitation stems from the fact that the low
levels of CYP3A in the brain require the application of
very sensitive methods to measure relatively low concentrations of the generated metabolites in this tissue.
We recently [26] developed a sensitive and specific
LC–MS/MS method to quantitate the CYP3A-mediated
hydroxylation of midazolam (MDZ) in the rat brain
MC. This study showed evidence of the metabolism of
MDZ to 10 - and 4-hydroxylated metabolites in the rat
brain MC, with higher production rates for the
4-hydroxylated metabolite [26]. In the current study, we
applied the method to determine the Michaelis–Menten
enzymatic kinetics of CYP3A activity in both microsomal and mitochondrial fractions of rat brains. Additionally, we used WB analysis to measure the levels of
CYP3A proteins in the brain MC and MT.

ALSHAMMARI ET AL.

metabolites of MDZ were procured from Cerilliant Corporation (Round Rock, TX, USA) and Sigma-Aldrich
(St. Louis, MO, USA), respectively. The stable isotopes
10 -hydroxymidazolam-d5
(10 -OH-MDZ-d5)
and
4-hydroxymidazolam-d5 methanoate (4-OH-MDZ-d5)
were purchased from Toronto Research Chemicals
(North York, ON, Canada). The primary antibodies
against
rat
CYP3A2
(ab195627),
calreticulin
(Ab92516), and VDAC1 (Ab15895) and the secondary
antibody (Ab6721) were purchased from Abcam
(Cambridge, MA, USA). All the other reagents and chemicals were of high purity and purchased from commercially available sources.

2.2 | Collection of rat brains
Adult male Sprague–Dawley rats (234–274 g) were
purchased
from
Charles
River
Laboratories
(Wilmington, MA, USA). The animals were housed in a
temperature- and humidity-controlled room under a
12 h light–dark cycle, with free access to food and
water. Under isoflurane anesthesia, whole-body perfusion with cold saline (0.9%, w/v) at a flow rate of 25 ml/
min was carried out for 8 min to remove the blood from
the brain and other organs. After the perfusion, brains
(without cerebellum or brain stem) were collected,
snap-frozen in liquid nitrogen, and stored at 80 C.
Animal studies were approved by the Institutional Animal Care and Use Committee of Chapman University.

2.3 | Preparation of rat brain
microsomal and mitochondrial fractions

2 | MATERIAL AND METHODS

Brain MC and MT were prepared by differential centrifugation, followed by Percoll density gradient purification
of MT as described before [27]. The final microsomal
and mitochondrial pellets were resuspended and
homogenized in the storage buffer and stored at
80 C. The composition of the storage buffer was
100 mM Tris (pH 7.4), 0.2 mM EDTA, 1.15% KCl, 20%
glycerol, 0.1 mM dithiothreitol, 22 μM butylated hydroxytoluene, and 0.1 mM phenylmethylsulfonyl fluoride.
The total protein concentrations of the MC and MT fractions were estimated in triplicates by the bicinchoninic
acid protein assay, using bovine serum albumin as
standard. The degree of purity of the MC and MT fractions was estimated by WB analysis of VDAC1 and calreticulin as described below.

2.1 | Chemicals, reagents, and
antibodies

2.4 | WB analysis

MDZ base was purchased from the United States Pharmacopeial Convention (Rockville, MD, USA). The 10 hydroxy (10 -OH-MDZ) and 4-hydroxy (4-OH-MDZ)

To estimate the relative contamination of purified MT
and MC with each other, we determined the presence
of calreticulin (an endoplasmic reticulum marker) and
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VDAC1 (a mitochondrial protein) in the fractions by WB
analysis [27]. Briefly, MC or MT proteins (10 μg) were
subjected to SDS-polyacrylamide gel electrophoresis
on a precast Bio-Rad (Hercules, CA, USA) 4% to 20%
MP TGX Stain-Free gel at constant voltage (200 V) for
30 min. After transferring the bands onto PVDF, the
membranes were blocked with 5% BSA for 1 h at room
temperature. Subsequently, membranes were incubated overnight (4 C) with the primary antibody (calreticulin at a dilution of 10 000 or VDAC1 at a dilution of
50 000). After washing, the membranes were incubated
with the horseradish peroxidase (HRP)-conjugated secondary antibody (a dilution of 50 000) and StepTactinHRP conjugate. The bands were visualized with the
Bio-Rad ChemiDoc Imaging system.
For WB analysis of CYP3A in the brain fractions,
40 μg MC or MT proteins were loaded on 4% to 15%
MP TGX Stain-Free gels (Bio-Rad) and electrophoresed at 120 V for 30–90 min before transferring the
bands onto PVDF membranes. The membranes were
blocked with 5% nonfat milk before overnight incubation (4 C) with the primary antibody against polyclonal
CYP3A2 antibody (2500 dilution). The secondary antibody incubation and imaging of the bands were as
described above for calreticulin and VDAC1, except
that a 5000 dilution of the secondary antibody was used
for CYP3A.
For all the WB analysis experiments, two gels were
used, each containing the MC and MT samples for four
rat brain samples. The MC and MT samples of the
same rat brain were loaded on the same gel, with alternating lanes containing MC and MT for each rat brain.
For calreticulin, the average intensities in the MC were
considered 100%, and the relative intensities of calreticulin impurities in the MT were calculated. For VDAC1,
the average intensities in the MT were considered
100%, and the relative intensities of VDAC1 impurities
in the MC were calculated. For CYP3A, the average
intensities in the MT were considered 100%, and the
relative intensities of CYP3A bands in the MC were
calculated.

2.5 | MDZ hydroxylation in microsomal
and mitochondrial fractions
The kinetics of MDZ 10 - and 4-hydroxylation in the brain
MC and MT fractions were assessed at substrate concentrations of 5 to 1000 μM for MC and 25 to 5000 μM
for MT. MDZ stock solutions (50 mM) were prepared by
dissolving the MDZ base powder in 105 mM HCl, followed by subsequent dilutions in 5 mM HCl. The incubation mixture (25 μl) contained 100 mM Tris–HCl
buffer (pH 7.4), 0.25 mg/ml rat brain MC or MT protein,
20 mM MgCl2, and 1 mM NADPH. The mixtures were
vortexed and preincubated for 5 min at 37 C. The reaction was initiated by the addition of the substrate (MDZ)
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and stopped after 10 min of incubation by the addition
of 75 μl acetonitrile, containing 10 nM each 10 -OHMDZ-d5 and 4-OH-MDZ-d5 as internal standards. The
reaction mixtures were vortexed, placed on ice for
5 min, centrifuged for 5 min at 13 400 rpm, and injected
onto the LC–MS/MS system. The incubation time of
10 min and the protein concentration of 0.25 mg/ml
were based on previous studies [26] investigating the
time and protein concentration linearity in MC.
In addition to the above experiments, the extent of
NADPH-independent production of the two hydroxylated metabolites of MDZ was studied at single substrate concentrations of 500 and 1250 μM for the brain
MC and MT, respectively. The incubation protocol was
as described above. However, samples were incubated
both with and without the addition of NADPH.

2.6 | Quantitation of the hydroxylated
metabolites of MDZ by LC–MS/MS
The concentrations of 10 -OH-MDZ and 4-OH-MDZ in
the incubation mixtures were determined based on a
previously reported method [26] after partial validation
of the method in both rat brain MC and MT in the current study. Briefly, the separation and quantitation of
the analytes were accomplished using EVOQ Elite
UPLC-MS/MS system (Bruker Scientific LLC; Billerica,
MA, USA) with a Kinetex 1.7 μm C18 (100  2.1 mm,
100 A) column (Phenomenex Inc; Torrance, CA, USA),
connected to a Phenomenex C18 Security Guard
ULTRA (2.1 mm) precolumn, which were maintained at
35 C. The gradient (0–1.2 min, 30% B; 1.2–5.0 min, linear gradient 30% to 70% B; 5.0–6.0 min, 70% B;
6.0 min, 30% B; 6.0–7.5 min, 30% B) mobile phase (A:
5 mM ammonium formate in water and B: acetonitrile)
was delivered at a flow rate of 0.25 ml/min. The ionization was achieved by electrospray in the positive mode,
with the m/z transitions of 342 to 202.9 for 10 -OH-MDZ,
342 to 233.9 for 4-OH-MDZ, 346.9 to 207.9 for 10 -OHMDZ-d5, and 346.9 to 234.9 for 4-OH-MDZ-d5.
The partial validation of the assay in MC and MT
was conducted using calibration curve standards
(25 μl), containing 0.25 mg/ml of the matrix (MC or MT)
in Tris–HCl buffer (pH 7.4), MgCl2 (20 mM), and 1 to
100 nM of both analytes plus quality control samples
(n = 5), prepared and analyzed on three different days.
The quality control samples contained 3, 30, or 80 nM
of each metabolite. After the addition of 75 μl of acetonitrile, containing 10 nM each 10 -OH-MDZ-d5 and
4-OH-MDZ-d5 as internal standards, and centrifugation,
5 μl of the standards or sample was injected onto the
LC–MS/MS. The intraday and interday precision of the
quality control samples were estimated from their relative standard deviations (%RSD). The accuracy of the
assay was estimated using the percent relative error
(%RE) based on the following equation:
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F I G U R E 1 Representative LC/MS–MS chromatograms of blank (a and e), the lowest (b and f), and the highest (c and g) calibration curve
standards of 10 -OH-MDZ and 4-OH-MDZ and their internal standards (IS) (d and h) in the microsomal (a–d) and mitochondrial (e–h) matrices.
The chromatograms related to 10 -OH-MDZ or its IS (solid lines) are overlayed with those of 4-OH-MDZ or its IS (dashed lines) for each sample.

%RE ¼ ðMeasured Concentration  Nominal ConcentrationÞ

100=Nominal Concentration:

and fraction (MC and MT). The intrinsic clearance
(CLint) and maximum clearance (CLmax) values for the
MM and Hill equations, respectively, were estimated
using the following equations [28]:
CLint ¼

2.7 | Data analysis

CL max ¼

The metabolism rate-substrate concentration profiles
for microsomal and mitochondrial fractions were analyzed using both Michaelis–Menten (MM) and Hill equations, described below, respectively [28]:
Formation Rate ¼

Formation Rate ¼

V max  S
,
KM þ S

V max  Sn
,
S50 n þ Sn

V max
,
KM

V max
ðn  1Þ

:
S50 nðn  1Þ1=n

The comparison of the MM or Hill model fit to each
data set was based on the Akaike’s information criterion (AIC). The statistical differences between the
microsomal and mitochondrial data were tested using a
two-tailed, t-test analysis. A P value of <0.05 was considered significant. All data analyses were performed
using GraphPad Prism software (La Jolla, CA, USA).

3 | RESULTS
where Vmax is maximum velocity; KM and S50 are the
substrate concentrations producing half of Vmax in the
MM and Hill equations, respectively; n is the Hill coefficient; and S is the substrate concentration. The nonlinear regression analysis was carried out using the
naïve pooled data from the eight brains, which generated Vmax, KM, S50, and n values and their variability
(SE) for each metabolite (10 -OH-MDZ and 4-OH-MDZ)

Representative chromatograms of 10 -OH-MDZ and
4-OH-MDZ in the microsomal and mitochondrial matrices, along with their internal standards, are presented
in Figure 1 for the blank and the lowest (1 nM) and
highest (100 nM) concentrations in the calibration
curves. As demonstrated in the figure, the chromatograms in the mitochondrial matrix (Figure 1, bottom
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F I G U R E 2 Calibration curves of 10 OH-MDZ (a and c) and 4-OH-MDZ
(b and d) in the microsomal (a and b) and
mitochondrial (c and d) matrices over
3 days. The mean and SD values of the
slopes for the two metabolites in the
microsomal and mitochondrial matrices
are also presented in a table at the
bottom of the figure. P values refer to the
differences between the microsomal and
mitochondrial slopes based on a twotailed unpaired t test.

F I G U R E 3 Representative Western blot (top panels) and individual densitometric data (bottom panels) for (a) VDAC1, (b) calreticulin, and
(c) CYP3A in rat brain microsomes (MC) and mitochondria (MT). Symbols represent individual brain data (n = 8), which are normalized based on
the values in the mitochondria (VDAC1 and CYP3A) or microsomes (calreticulin), and the horizontal lines represent the mean values.
***
P < 0.001; ****P < 0.0001; based on two-tailed paired t test.

panels) were almost identical to those in the microsomal samples (Figure 1, top panels). In agreement
with the chromatographic data, the slopes of the calibration curves in the mitochondrial matrix were not significantly different from those in the microsomal
samples for either 10 -OH-MDZ or 4-OH-MDZ (Figure 2).
Figure 2 also demonstrates relatively minor day-to-day
variability in the slopes of the calibration curves for both
metabolites and fractions. The intraday and interday
precision and relative error values (individual data not

shown) were ≤11.5% and between 8.52% and
15.6%, respectively, for both metabolites and matrices.
The largest relative error (15.6%) belonged to the 3 nM
microsomal concentration of the 10 -OH-MDZ quality
control sample for the intraday data on Day 1. These
data collectively indicate the assay’s suitability for
quantitation of 10 -OH-MDZ and 4-OH-MDZ in both
microsomal and mitochondrial samples.
The WB data for the presence of the microsomal
(calreticulin) and mitochondrial (VDAC1) markers and
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F I G U R E 4 The formation ratesubstrate concentration plots of 10 -OHMDZ (a and b) and 4-OH-MDZ (c and d)
in the rat brain microsomes (a and c) and
mitochondria (b and d). The metabolism
studies were conducted using
0.25 mg/ml microsomal or mitochondrial
protein with MDZ concentrations of 0–
1000 μM for microsomes and 0–5000 μM
for mitochondria and an incubation time
of 10 min (n = 8 different brains). The
symbols and error bars represent the
mean and SE, respectively, and the lines
represent the nonlinear regression fit of
the experimental data to the MM
equation (10 -OH-MDZ) or Hill equation
(4-OH-MDZ).

T A B L E 1 The model estimates (SE) of Michaelis–Menten (10 -OH-MDZ) or Hill (4-OH-MDZ) equation kinetic parameters for the
hydroxylated metabolites of MDZ in rat brain microsomes and mitochondria (n = 8 brains)
Parametera

Microsomes

Mitochondria

0.283  0.022

2.56  0.67**

KM (μM)

21.7  15.1

3330  1640*

CLint (μl/min/mg)

0.0130

0.000768

Vmax (pmol/min/mg)

8.88  1.77

21.4  5.3*

S50 (μM)

344  126

1550  620

n

1.39  0.22

1.61  0.36

CLmax (μl/min/mg)

0.0143

0.00709

0

1 -OH-MDZ (Michaelis–Menten equation)
Vmax (pmol/min/mg)

4-OH-MDZ (Hill equation)

a
Vmax, maximum velocity; KM or S50, the substrate concentration producing half of Vmax; n, the Hill coefficient; CLint, intrinsic clearance; and CLmax, maximum
clearance.
*
P < 0.05; two-tailed unpaired test, compared with microsomes.
**
P < 0.01; two-tailed unpaired test, compared with microsomes.

CYP3A in the prepared MC and MT fractions are presented in Figure 3. The VDAC1 contents of the microsomal fractions (mean  SD) were 5.93%  3.01% of
the mitochondrial VDAC1 (Figure 3a), suggesting minor
contamination of the MC with the MT. As for the contamination of MT with MC, the calreticulin contents of
the mitochondrial fraction were 19.3%  7.8% of the
microsomal calreticulin (Figure 3b). The CYP3A contents of the MC (49.3%  13.3%) were twofold less
than those in the mitochondrial fractions (100%  9%)
(Figure 3c).
The formation rate-substrate concentration plots for
10 -OH-MDZ and 4-OH-MDZ in the microsomal and
mitochondrial fractions are presented in Figure 4. Additionally, the corresponding model-generated kinetic
parameters Vmax, KM, S50, and n values are presented

in Table 1. Whereas the best fit model for the formation
of 10 -OH-MDZ was the MM equation, the Hill equation
with an n value of >1 was a better fit for 4-OH-MDZ
(Figure 4 and Table 1). For both metabolites, the maximum formation rates in MT (Figure 4b,d) were substantially higher than those in MC (Figure 4a,c). Comparing
the two metabolites, the formation rates of 4-OH-MDZ
(Figure 4c,d) were substantially higher than those for
10 -OH-MDZ (Figure 4a,b) in both MC and MT. Among
the metabolites and fractions, the formation rates of 10 OH-MDZ in MC (Figure 4a) were the lowest and at or
close to the limit of the detection of the assay. In terms
of the kinetic parameters, the Vmax values of 1-OHMDZ and 4-OH-MDZ formation in MT were, respectively, 9- and 2.4-fold higher than the corresponding
values in the MC (Table 1). Additionally, the KM or S50
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values of both metabolites in MT were higher than
those in the MC, although the difference for 4-OH-MDZ
did not reach statistical significance (P = 0.059) due,
perhaps, to large variability in the data (Table 1).
Despite higher Vmax values in MT, the secondary
parameters CLint and CLmax were lower in this fraction
because of higher KM/S50 values in MT (Table 1).
The production rates of the hydroxylated metabolites (mean  SD) in eight different brains in the
absence of added NADPH, as a percentage of the total
rate in the presence of NADPH, were 32.1%  7.5%
(MC) and 15.6%  9.1% (MT) for 10 -OH-MDZ and
39.9%  9.9% (MC) and 38.9%  14.4% (MT) for
4-OH-MDZ.

4 | DISCUSSION
In this study, we used MDZ as a substrate probe for the
determination of the CYP3A activity [29–31]. MDZ
undergoes hydroxylation by CYP3A isoforms to produce 10 -OH-MDZ, which is an active metabolite, and
4-OH-MDZ, which is inactive [32]. Additionally, MDZ is
a short-acting benzodiazepine used therapeutically for
anesthesia induction and as a sedative [33]. In
humans, 10 -OH-MDZ and 4-OH-MDZ constitute approximately 60% to 80% and 5%, respectively, of the systemic (i.e., primarily liver) biotransformation products of
MDZ [34]. In the current study, we showed that CYP3A
activity, as demonstrated by MDZ hydroxylation, is present in both rat brain MT and MC (Figure 4). However,
the MDZ hydroxylation activities in MT are significantly
higher than those in MC for both metabolites. Additionally, in both fractions, the formation rates of 4-OH-MDZ
were much higher than those for 10 -OH-MDZ (Figure 4
and Table 1).
Although we recently [26] showed in a preliminary
study that CYP3A-mediated hydroxylation of MDZ
occurs in the rat brain MC, clear evidence for the
CYP3A enzymatic activity and its kinetics in the brain
MT have been lacking in the literature. In 1992, Jayyosi
et al. [19] were able to detect small quantities of 6βhydroxytestosterone in the rat brain MC after their incubation with testosterone. Testosterone is believed to be
converted to its 6β-hydroxylated metabolite through
CYP3A. The authors also reported the presence of a
prominent immunoreactive band in the brain MT and a
slight band in the brain MC in response to the antibody
to cytochrome P450p, which has 89% amino acid
sequence homology with CYP3A2. However, the significantly prominent band in the MT was associated with
40% less 6β-hydroxytestosterone formation in the MT
relative to that in the MC. Additionally, the antibody
against cytochrome P450p did not have any inhibitory
effect on the formation of 6β-hydroxytestosterone.
Therefore, these studies were inconclusive with regard
to the presence or activity of CYP3A in the rat brain
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MT. Indeed, the authors concluded that the role of the
cytochrome P450p-related immunoreactive protein in
the rat brain MT needed to be determined in future
studies.
Consistent with the higher formation rates of both
hydroxylated metabolites in the MT fractions (Figure 4),
the CYP3A protein expression in the MT was almost
twice as that in MC (Figure 3c). Using WB analysis,
Rosenbrock et al. [25] were able to demonstrate the
presence of CYP3A in the rat brain MC. They also
showed that the CYP3A band intensities in the rat brain
MC were substantially lower than those in the liver
MC. A subsequent study using anti-CYP3A1 antibodies
in the mouse brain by the same group [21] revealed the
presence of a phenytoin-inducible CYP3A in the MC
and a constitutive CYP3A in the MT. In agreement with
our results in rat brains (Figure 3c), the band intensities
in the mouse MT of control (uninduced) animals were
significantly higher than those in the MC [21].
RT-PCR and Northern blot studies have reported
the presence of various CYP3A isoforms such as
CYP3A1/23 [35, 36] and CYP3A9 [37] in the rat brain.
Similar to the brain, at least five isoforms of CYP3A,
including CYP3A1/23 and CYP3A2 have been identified in the rat liver [37]. However, a direct comparison
between the rat liver and brain tissues indicated that
the mRNA content of brain CYP3A1 was only 0.02% of
that in the liver [35]. In our WB studies, we used a
CYP3A2 polyclonal antibody to detect CYP3A proteins
in the rat brain MC and MT. However, it is highly likely
that the polyclonal antibody used in our experiments
cross reacts with other isoforms of CYP3A. Therefore,
the identity of CYP3A isoform(s) detected in our WB
experiments (Figure 3c) and responsible for the MDZ
hydroxylation activity in the rat brain MC and MT
(Figure 4 and Table 1) cannot be determined from
these experiments.
Previous studies in human and rat brain MC have
revealed an important role for the brain CYP3A in the
local metabolism of major centrally acting drugs such
as amitriptyline [20] and alprazolam [22, 23]. Amitriptyline was N-demethylated to nortriptyline by both human
and rat brain MC. This metabolism was inhibited by
ketoconazole, a chemical inhibitor of CYP3A, and a
specific monoclonal antibody towards CYP3A. However, the amitriptyline N-demethylase activity of the rat
liver was 250 times higher than that in the rat brain [20].
Additionally, alprazolam, another benzodiazepine with
structural similarity to MDZ, is metabolized to both 10 hydoxyalprazolam
(active
metabolite)
and
4-hydroxyalprazolam (inactive metabolite) in the human
brain. Similar to our studies with MDZ in rat brain MC
(Table 1), a previous study [22] showed the Vmax
values for the 4-hydroxylated metabolite of alprazolam
in both rat and human brain MC were higher than those
for the 10 -hydroxylated metabolite. Additionally, relative
to 4-OH-MDZ, more 10 -hydroxyalprazolam was formed
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in the brain than in the liver [22]. Therefore, the local
metabolism of drugs by CYP3A in the brain can potentially affect the pharmacodynamics of centrally acting
drugs.
For MDZ, studies in human and rat liver MC showed
opposite regioselectivity for the formation of its hydroxylated metabolites, with the human liver MC preferentially forming the more active 10 -hydroxylated
metabolite [31]. Because the hydroxylated metabolites
cannot cross the blood–brain barrier, the regioselectivity in the metabolism of MDZ locally in the brain, as
opposed to that in the liver, is expected to have a more
prominent influence on the pharmacologic activities of
the drug. In our current studies, the higher Vmax values
of both metabolites in the mitochondrial fraction, relative to MC (Table 1), were also associated with the
higher relative abundance of the more active 10 -OHMDZ in the MT. The pharmacological relevance of the
relatively higher formation rates of the more active 10 OH-MDZ in the MT, compared with MC, remains to be
investigated in future studies.
Microsomal and mitochondrial electron transfer systems for P450 reactions differ from each other [38]. In
MC, NADPH-cytochrome P450 reductase (CPR) is
required for electron transfer in P450-mediated reactions. Because both CPR and P450 are integral membrane bound proteins, in vitro preparation of MC is not
expected to affect their relative abundance in MC. On
the other hand, the electron transfer in MT occurs
through the adrenodoxin/adrenodoxin reductase system, which are soluble proteins present in the inner
membrane matrix of MT. Due to the potential disruption
of some MT membranes during the in vitro preparation
of MT, the concentrations of these soluble proteins in
the MT matrix may be reduced [39]. Therefore, the
in vitro metabolic activities of MT (Table 1) may be
underestimations of their true in vivo activities. Specifically, the much higher KM/S50 values in MT, compared
with those in MC, might be due, at least in part, to the
in vitro loss of adrenodoxin/adrenodoxin reductase system during the preparation of MT. However, the presence of different isoforms of CYP3A, with different
affinities, in the MC and MT fractions cannot be ruled
out as a culprit for the observed differences between
MC and MT in their KM/S50 values (Table 1).
Our studies in the absence of added NADPH to the
incubation mixtures showed generation of both hydroxylated metabolites of MDZ in both MC and MT fractions
at rates equal to 16% to 40% of those observed in the
presence of added NADPH. The exact mechanisms for
this observation are not clear. However, these reactions in the absence of added NADPH could potentially
be due to residual NADPH in the fractions and/or
NADPH-independent hydroxylation of MDZ. The potential role of residual NADPH might be higher for the MT
fractions because NADPH cannot easily cross intracellular membranes such as intact mitochondrial
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membranes [40]. Additionally, the presence of residual
NADPH in the microsomal fractions cannot be ruled out
[41]. The residual NADPH, if any, could play a more
significant role in the P450-mediated metabolism in the
brain preparations, which have very low P450 contents
and thus lower NADPH requirement, compared with
the liver preparations.
Assuming the observed in vitro differences between
the MC and MT in their formation rates of the MDZ
metabolites (Table 1) are transferrable to in vivo, the
contribution of MT to the in vivo metabolism of MDZ in
the brain may not be significant after therapeutic doses.
This is because of high KM/S50 and low CLint/CLmax
values in the mitochondrial fraction (Table 1) and much
lower concentrations of MDZ in the brain after therapeutic doses compared with the very high substrate
ranges used in our in vivo study, in particular for the
mitochondrial fraction (Figure 4). For example, the
steady-state brain concentrations of free MDZ after
intravenous infusion of 20–40 mg of MDZ per hour in
humans were lower than 1 μM [42]. At similar concentrations (<1 μM) in rat brains, which are much lower
than the KM or S50 values for the hydroxylated metabolites (Table 1), the contribution of MC to the metabolism
of MDZ would be higher than that of MT as reflected in
the CLint and CLmax values (Table 1). It should be noted
that in vivo extrapolations are much more complex and
should also consider the relative abundance of microsomal and mitochondrial proteins and their contribution
to the total CYP3A contents in the brain tissue.
The MDZ hydroxylation activities reported in our
study showed substantial interanimal variability
(Figure 4). The variability in the activities (Figure 4) were
in general larger than the degree of variability in the
CYP3A immunoreactive proteins in MC and MT
(Figure 3c). Despite high formation rates at high substrate concentrations, the MDZ hydroxylation activities
remained highly variable in MT, especially for 4-OHMDZ (Figure 4d). The high variability in the MT activities
relative to the variability in the MT content of CYP3A
may be due, at least in part, to variability in the loss of
MT electron-donating system (adrenodoxin/adrenodoxin
reductase) during the preparation of MT fraction discussed above. Nevertheless, the high inter-animal variability in the CYP3A-mediated metabolism of MDZ is not
unique to rat brain or MT fraction as it has been
observed in other species and tissues [43, 44].

5 | CONCLUSION
In conclusion, we demonstrated CYP3A-mediated
hydroxylation of MDZ to 10 -OH-MDZ and 4-OH-MDZ in
both rat brain MC and MT. Whereas MC showed a
high-affinity, low-capacity CYP3A activity, the hydroxylation of MDZ in the MT was governed by a low-affinity,
high-capacity process. The high capacity of the enzyme
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in the MT was also associated with a higher protein
expression of CYP3A in this fraction. Additionally, in
both fractions, the formation rate of the 4-hydroxylated
metabolite was higher than that for 10 -OH-MDZ. The
presence of CYP3A activity in the brain MT with high
capacity may have pharmacological or toxicological
ramifications for the centrally acting drugs or other
xenobiotics, which are metabolized by this enzyme.
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